Patents by Inventor Rudolf Kunze

Rudolf Kunze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides having binding affinity to an antibody which recognizes an epitope on an ?1 loop 2 or ?2 loop 1 of an adrenoreceptor
    Patent number: 9574017
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: February 21, 2017
    Assignees: MDC Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
  • PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN ALPHA1 LOOP 2 OR BETA2 LOOP 1 OF AN ADRENORECEPTOR
    Publication number: 20130302292
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Application
    Filed: April 26, 2013
    Publication date: November 14, 2013
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
  • Peptides having binding affinity to an antibody which recognizes an epitope on an ?1 loop 2 or ?2 loop 1 of an adrenoreceptor
    Patent number: 8455442
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: June 4, 2013
    Assignees: MDC Max-Delbruck-Centrum fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
  • Pharmaceutical compositions comprising gamma secretase modulators
    Publication number: 20110251220
    Abstract: The present invention relates to pharmaceutical compositions comprising gamma secretase modulators as well as to the use of gamma secretase modulators for treating renal disorders, cancer, neurodegenerative disorders as well as related disorders.
    Type: Application
    Filed: June 2, 2009
    Publication date: October 13, 2011
    Inventors: Özlem Acikgöz, Jessica Ahmed, Bernd Dörken, Cornelius Frömmel, Andrean Goede, Franziska Jundt, Rudolf Kunze, Robert Preissner
  • PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN A1 LOOP 2 OR BETA2 LOOP 1 OF AN ADRENORECEPTOR
    Publication number: 20110104226
    Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 5, 2011
    Inventors: Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
  • PEPTIDES AGAINST AUTOANTIBODIES ASSOCIATED WITH GLAUCOMA AND USE OF THESE PEPTIDES
    Publication number: 20090220469
    Abstract: The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma.
    Type: Application
    Filed: March 9, 2007
    Publication date: September 3, 2009
    Applicants: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH, FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBER G
    Inventors: Gerd Wallukat, Rudolf Kunze, Martin Herrmann, Reinhard Voll, Anselm Junemann, Ursula Schloetzer
  • Peptides, the production and use thereof for binding immunoglobulins
    Patent number: 7205382
    Abstract: Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence: R1-X01-X02-X03-X04-X05-X06-X07-X08-X09-X10-X11-X12-X13-R2. These peptides have a high affinity for immunoglobulins. Applications of the peptides according to the invention are also described.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: April 17, 2007
    Assignee: Fresenius Medical Care Affina GmbH
    Inventors: Wolfgang Rönspeck, Ralf Egner, Dirk Winkler, Rudolf Kunze
  • Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (DCM)
    Patent number: 6994970
    Abstract: Peptides which bind auto-antibodies being in a causally pathological relationship with dilatative cardiomyopathy are described. The peptides may be bound, for example, to a solid phase. Auto-antibodies can be removed by treating blood of patients suffering from DCM with the peptides according to the invention.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: February 7, 2006
    Assignee: Fresenius Medical Care Affina GmbH
    Inventors: Wolfgang Rönspeck, Rudolf Kunze, Gerd Wallukat, Manuela Dierenfeld
  • Peptides, the production and use thereof for binding immunoglobulins
    Publication number: 20040087765
    Abstract: Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence:
    Type: Application
    Filed: August 8, 2003
    Publication date: May 6, 2004
    Inventors: Wofgang Ronspeck, Ralf Egner, Dirk Winkler, Rudolf Kunze
  • METHOD OF STIMULATING THE EXPRESSION OF CYTOKINES IN MAMMALS USING SUGAR-PROCESSINIG ENZYMES AND NUTRITIONAL SUPPLEMENTS CONTAINING SUCH ENZYMES
    Publication number: 20020071836
    Abstract: Sugar-processing enzymes are used in a method of stimulating the expression of anti-inflammatory cytokines by mammalian peripheral blood cells and are incorporated into nutritional supplements. The preferred sugar-processing enzymes are cellulases and glucolytic enzymes.
    Type: Application
    Filed: June 10, 1999
    Publication date: June 13, 2002
    Inventors: JOACHIM LEHMANN, AFTAB J. AHMED, RUDOLF KUNZE
  • Water-soluble low molecular weight beta-glucans for modulating immunological responses in mammalian system
    Patent number: 6143883
    Abstract: A fractionated, water-soluble, readily absorbable, low molecular weight beta-glucan is usable as an immune-modulator in the mammalian system. A method is disclosed, which produces a fractionated beta-glucan that is water-soluble and has a molecular weight between 1,000 Daltons-30,000 Daltons (1 kD-30 kD) adaptable to affect changes in the immune responses in mammalian systems.
    Type: Grant
    Filed: December 31, 1998
    Date of Patent: November 7, 2000
    Assignee: Marlyn Nutraceuticals, Inc.
    Inventors: Joachim Lehmann, Rudolf Kunze
  • Use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in pregnant women with habitual idiopathic abortion in their anamneses
    Patent number: 5505942
    Abstract: The present invention relates to the use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in pregnant women in need thereof with habitual idiophathic abortion in their anamneses.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: April 9, 1996
    Assignee: Mucos Pharma GmbH & Co.
    Inventors: Karl Ransberger, Friedrich-Wilhelm Dittmar, Rudolf Kunze, Gerhard Stauder